Wave Life Sciences will deliver third quarter earnings update: Can WVE break above $3.49?

Wave Life Sciences will deliver third quarter earnings update: Can WVE break above $3.49?
Wave Life Sciences stock edges higher

Wave Life Sciences plans to release its third quarter earnings update on October 27. The stock edges higher on the day, trading at $3.38.

Highlights

  • Wave Life Sciences will report third quarter earnings on October 27 with a webcast open to registered listeners.
  • 66 of 70 analysts rate Wave Life Sciences stock a buy, with a median price target of $14.
  • Shares of Wave Life Sciences trade at $3.38.

Wave Life Sciences will deliver its third quarter earnings update on Tuesday, October 27. The company is inviting interested listeners to register and join the webcast for the event. Wave Life Sciences operates in the biotechnology sector, with 287 employees and a market capitalization of about $1.2 billion on revenue of $65.3 million over the trailing twelve months.

Early gains fade as price stays below key moving averages

Shares of Wave Life Sciences opened the session with a gap up at $3.42 from the previous close of $3.37, but have since given back part of those early gains. The broader daily chart remains bearish, as price continues to trade below its MA-20, MA-50, and MA-200. The nearest resistance sits at the weekly high of $3.49, and RSI at 37.5 is nearing oversold territory, suggesting the decline is getting stretched and may support some stabilization.

Downside odds dominate as traders eye weekly high versus $3.08

Traders should watch for a close above the weekly high at $3.49 to indicate buyers are willing to push higher. Price opened with a gap up from $3.37 to $3.42, with some of that move retracing as the session progressed. Even after a sustained move higher with a firm trend over the past week, the probabilities over the next five trading days are 28% for upside and 72% for downside, with an expected trading range between $3.19 and $3.56. A close below $3.08 would show the move is being faded. On the weekly chart the longer-term picture stays negative.

Earlier, analysts noted that Wave Life Sciences was under sustained bearish pressure despite developments in its clinical pipeline. With the technical outlook still tilted to the downside ahead of the company's earnings update, traders should monitor a close above $3.49 as a potential signal for renewed upward momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.